FOUNDATION FOR THE NATIONAL INSTITUTE OF HEALTH INC: Form 990, tax year 2022
View the entire original 990 at ProPublica ↗
- Organization
- FOUNDATION FOR THE NATIONAL INSTITUTE OF HEALTH INC (EIN 52-1986675)
- Tax period
- 2022-01-01 to 2022-12-31
- Filed
- 2023-11-13
- IRS object ID
- 202313179349303941
- Schema version
- 2022v5.0
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule G
- Schedule I
- Schedule J
- Schedule M
- Schedule O
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2023-11-13T10:57:54-06:00 | ReturnTs |
| Tax Period End | 2022-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 440160260 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | FORVIS LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 901 EAST CARY STREET SUITE 1000 | AddressLine1Txt |
| City | RICHMOND | CityNm |
| State Abbreviation | VA | StateAbbreviationCd |
| ZIP | 23219 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2022-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 521986675 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | FOUNDATION FOR THE NATIONAL INSTITUTES | BusinessNameLine1Txt |
| Business Name Line2 | OF HEALTH INC | BusinessNameLine2Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | FOUN | BusinessNameControlTxt |
| Phone | 3014025311 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 11400 ROCKVILLE PIKE 600 | AddressLine1Txt |
| City | NORTH BETHESDA | CityNm |
| State Abbreviation | MD | StateAbbreviationCd |
| ZIP | 20852 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | DR JULIE L GERBERDING | PersonNm |
| Person Title | CHIEF EXECUTIVE OFFICER | PersonTitleTxt |
| Phone | 3014025311 | PhoneNum |
| Signature | 2023-11-09 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Signing Officer SigningOfficerGrp
Person Full Name PersonFullName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person First | DR | PersonFirstNm |
| Person Last | JULIE L GERBERDING | PersonLastNm |
| Field | Value | IRS element (for citing) |
|---|---|---|
| SSN | 999009999 | SSN |
| Field | Value | IRS element (for citing) |
|---|---|---|
| IRS Responsible Prty Info Curr | Yes (1) | IRSResponsiblePrtyInfoCurrInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | LAKRISHA J CASTLEBERRY | PreparerPersonNm |
| PTIN | P01677333 | PTIN |
| Phone | 8042827636 | PhoneNum |
| Preparation | 2023-11-09 | PreparationDt |
Additional Filer Information AdditionalFilerInformation
Trusted Customer TrustedCustomerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Trusted Customer | 2 | TrustedCustomerCd |
| Authentication Assurance Level | AAL1 | AuthenticationAssuranceLevelCd |
| Identity Assurance Level | IAL1 | IdentityAssuranceLevelCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2022 | TaxYr |
| Build TS | 2023-04-26 12:10:37Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | DONALD M HILL | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 11400 ROCKVILLE PIKE 600 | AddressLine1Txt |
| City | NORTH BETHESDA | CityNm |
| State Abbreviation | MD | StateAbbreviationCd |
| ZIP | 20852 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $209,200,907 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | HTTP://WWW.FNIH.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1996 | FormationYr |
| Legal Domicile State | MD | LegalDomicileStateCd |
| Activity Or Mission | THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH (FNIH) CONNECTS THE WORLD'S LEADING PUBLIC AND PRIVATE ORGANIZATIONS TO ACCELERATE BIOMEDICAL BREAKTHROUGHS FOR PATIENTS, REGARDLESS OF WHO THEY ARE, WHERE THEY LIVE, OR WHAT DISEASE THEY HAVE. TOGETHER WITH LEADING SCIENTISTS AND PROBLEM-SOLVERS, AND A SUCCESSFUL TRACK RECORD OF NAVIGATING COMPLEX PROBLEMS, THE FNIH ACCELERATES NEW THERAPIES, DIAGNOSTICS, AND POTENTIAL CURES; ADVANCES GLOBAL HEALTH AND EQUITY IN CARE; AND CELEBRATES AND TRAINS THE NEXT GENERATION OF SCIENTISTS. ESTABLISHED BY CONGRESS IN 1990 TO SUPPORT THE MISSION OF THE NATIONAL INSTITUTES OF HEALTH (NIH), THE FNIH IS A NOT-FOR-PROFIT 501(C)(3) CHARITABLE ORGANIZATION. FOR MORE INFORMATION ABOUT THE FNIH, PLEASE VISIT FNIH.ORG. | ActivityOrMissionDesc |
| Voting Members Governing Body | 25 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 24 | VotingMembersIndependentCnt |
| Total Employee | 90 | TotalEmployeeCnt |
| Total Volunteers | 24 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $105,993,785 | PYContributionsGrantsAmt |
| CY Contributions Grants | $68,998,263 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $50,000 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $50,000 | CYProgramServiceRevenueAmt |
| PY Investment Income | $1,523,894 | PYInvestmentIncomeAmt |
| CY Investment Income | $1,459,757 | CYInvestmentIncomeAmt |
| PY Other Revenue | $38,012 | PYOtherRevenueAmt |
| CY Other Revenue | $77,179 | CYOtherRevenueAmt |
| PY Total Revenue | $107,605,691 | PYTotalRevenueAmt |
| CY Total Revenue | $70,585,199 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $20,925,571 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $32,121,575 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $11,200,771 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $12,734,826 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $142,183 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $26,276,294 | PYOtherExpensesAmt |
| CY Other Expenses | $32,561,709 | CYOtherExpensesAmt |
| PY Total Expenses | $58,402,636 | PYTotalExpensesAmt |
| CY Total Expenses | $77,418,110 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $49,203,055 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | -$6,832,911 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $221,939,759 | TotalAssetsBOYAmt |
| Total Assets EOY | $216,582,542 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $10,990,437 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $18,255,107 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $210,949,322 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $198,327,435 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | SEE SCHEDULE O, STATEMENT OF ORGANIZATION'S PRIMARY EXEMPT PURPOSE STATEMENTTO CREATE AND LEAD ALLIANCES AND PUBLIC-PRIVATE PARTNERSHIPS THAT ADVANCE BREAKTHROUGH BIOMEDICAL DISCOVERIES AND IMPROVE THE QUALITY OF PEOPLE'S LIVES | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $69,214,470 | ExpenseAmt |
| Grant | $31,578,039 | GrantAmt |
| Revenue | $50,000 | RevenueAmt |
| Desc | SEE SCHEDULE O, PROGRAM ONE, RESEARCH PROGRAMSPROGRAM ONE - RESEARCH PROGRAMS -ACCELERATING MEDICINES PARTNERSHIP PROGRAM (AMP) THE FNIH MANAGES THE ACCELERATING MEDICINES PARTNERSHIP (AMP) PROGRAM WITH THE INTERESTS OF THE COLLECTIVE SCIENTIFIC AND MEDICAL RESEARCH COMMUNITIES IN MIND. OUR MISSION IS TO IMPROVE UNDERSTANDING OF DISEASE PATHWAYS, FACILITATE BETTER SELECTION OF TARGETS FOR TREATMENT, AND IDENTIFY PLATFORMS AND PROCESSES TO ACCELERATE NEW AND EFFECTIVE THERAPIES TO PATIENTS.ALL AMP PROJECTS OPERATE UNDER THE BROAD PRINCIPLE OF DELIVERING PRE-COMPETITIVE ADVANCEMENTS TO THE RESEARCH AND MEDICAL FIELDS AND ENABLING THE BROADEST POSSIBLE ACCESS AND USE OF AMP RESEARCH DISCOVERIES. A CRITICAL COMPONENT OF EACH PUBLIC-PRIVATE PARTNERSHIP IN THE AMP PROGRAM IS AN AGREEMENT AMONG PARTNERS TO MAKE DATA AND ANALYSES ARISING FROM THE COLLABORATION PUBLICLY ACCESSIBLE TO BENEFIT THE BROADER BIOMEDICAL COMMUNITY. INDIVIDUAL AMP PROJECTS FREQUENTLY ESTABLISH PUBLIC PORTALS TO RAPIDLY DISSEMINATE DATA FROM THEIR RESEARCH EFFORTS, AND AMP-FUNDED PUBLICATIONS ARE REQUIRED TO BE MADE AVAILABLE PUBLICLY WITHIN SPECIFIC TIMEFRAMES.AT THE CENTER OF THE AMP PROGRAM IS A COMMON GOAL OF ACCELERATING NEW AND EFFECTIVE THERAPIES TO PATIENTS. AMP PROJECTS WORK TOWARDS THIS GOAL BY IDENTIFYING CLINICALLY RELEVANT DISEASE TARGETS, IMPROVING IDENTIFICATION OF PATIENTS MOST LIKELY TO RESPOND TO A PARTICULAR TREATMENT, AND SAFELY REDUCING THE DEVELOPMENT TIMELINES FOR LIFE-SAVING THERAPIES AND IMPROVEMENTS IN PATIENT OUTCOMES.ACTIV IN MARCH 2020, AS THE RAPIDLY DEVELOPING THREAT OF THE COVID-19 PANDEMIC BECAME CLEARER, OFFICIALS OF THE NIH AND THE FNIH SPEEDILY ASSEMBLED A GOVERNMENT-INDUSTRY-ACADEMIA COALITION TO COORDINATE RESEARCH AND CLINICAL TESTING EFFORTS TO COUNTER THE VIRUS. THE RESULTING PARTNERSHIP IS CALLED ACTIV (ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES) AND INCLUDES EIGHT U.S. GOVERNMENT AGENCIES, 20 BIOPHARMACEUTICAL COMPANIES, AND SEVERAL NONPROFIT ORGANIZATIONS, WITH THE MISSION OF DEVELOPING A RESEARCH STRATEGY FOR PRIORITIZING AND SPEEDING DEVELOPMENT OF THE MOST PROMISING COVID-19 VACCINES AND THERAPEUTICS.ACTIV REPLACED A PLETHORA OF SMALL INDIVIDUAL TRIALSMANY TOO SMALL OR INADEQUATELY DESIGNED TO PRODUCE MEANINGFUL RESULTSWITH A NATIONAL RESEARCH AGENDA FOR DEVELOPING THERAPEUTIC COUNTERMEASURES TO THE PANDEMIC AND PROVIDED SUPPORT FOR VACCINE DEVELOPMENT EFFORTS. ACTIV STANDS AS A MODEL FOR HOW THE BIOMEDICAL RESEARCH COMMUNITY CAN BE EFFECTIVELY MOBILIZED IN RESPONSE TO A GLOBAL PUBLIC HEALTH CRISIS.BIOMARKERS CONSORTIUM THE BIOMARKERS CONSORTIUM CONVENES GOVERNMENT, INDUSTRY, PATIENTS AND PATIENT ADVOCACY GROUPS, AND NOT-FOR-PROFIT ORGANIZATIONS TO ADDRESS ONE OF THE MOST PRESSING NEEDS IN THE DIAGNOSIS AND TREATMENT OF DISEASE: THE DEVELOPMENT AND THE SEEKING OF REGULATORY APPROVAL FOR DISEASE BIOMARKERS AND SURROGATES. THE BIOMARKERS CONSORTIUM CREATES AND LEADS CROSS-SECTOR EFFORTS THAT VALIDATE AND QUALIFY BIOMARKERS AND OTHER DRUG DEVELOPMENT TOOLS TO ACCELERATE BETTER DECISION MAKING FOR THE DEVELOPMENT OF NEW THERAPEUTICS AND HEALTH TECHNOLOGIES.THE CORE OPERATIONS OF THE BIOMARKERS CONSORTIUM ARE SUPPORTED THROUGH CONTRIBUTING MEMBERSHIP. ORGANIZATIONS REPRESENTING PRIVATE INDUSTRY (INCLUDING THE PHARMACEUTICAL, BIOTECHNOLOGY, DIAGNOSTICS, AND INFORMATION TECHNOLOGY INDUSTRIES) AND NOT-FOR-PROFIT ORGANIZATIONS (INCLUDING ASSOCIATIONS, ADVOCACY GROUPS, TRADE ORGANIZATIONS, AND PHILANTHROPIC ORGANIZATIONS) THAT WISH TO SUPPORT BIOMARKERS DEVELOPMENT ARE ELIGIBLE TO BECOME CONTRIBUTING MEMBERS.GENECONVENE THE GENECONVENE GLOBAL COLLABORATIVE ADVANCES BEST PRACTICES AND INFORMED DECISION MAKING FOR DEVELOPMENT OF GENETIC BIOCONTROL TECHNOLOGIES TO IMPROVE PUBLIC HEALTH. GENECONVENE OFFERS TECHNICAL INFORMATION, ADVICE, TRAINING, AND COORDINATION FOR RESEARCH ON GENE DRIVE AND OTHER GENETIC BIOCONTROL TECHNOLOGIES TECHNOLOGIES THAT USE GENETIC VARIANTS OF A TARGET SPECIES, LIKE A DISEASE-TRANSMITTING MOSQUITO, TO CONTROL ITS UNDESIRABLE IMPACTS. EFFORTS TO CONTROL THE SPREAD OF MOSQUITO-BORNE DISEASES SAVE HUNDREDS OF THOUSANDS OF LIVES EVERY YEAR, BUT THE TOOLS AND RESOURCES AVAILABLE ARE NOT SUFFICIENT TO PROTECT EVERYONE. GENE DRIVE IS RECOGNIZED AS A POTENTIALLY POWERFUL TOOL TO HELP CONTROL MALARIA. GENETIC BIOCONTROL HAS BEEN USED ON DISEASE-TRANSMITTING MOSQUITOES FOR OVER 60 YEARS, BUT SCIENTIFIC ADVANCES IN THE PAST 20 YEARS HAVE DRAMATICALLY IMPROVED THE ABILITY OF RESEARCHERS TO ENGINEER NEW GENETIC BIOCONTROL APPROACHES, INCLUDING GENE DRIVES. GENECONVENE WAS CREATED TO SUPPORT INFORMED DECISION MAKING ON THE OPEN SCIENTIFIC, REGULATORY, AND POLICY QUESTIONS RAISED BY THESE NEW TECHNOLOGIES.RESEARCH PROGRAMS FOR ACCELERATING NEW THERAPIESIMPROVING HEART HEALTH WITH THE AMP HEART FAILURE PROGRAMTHE ACCELERATING MEDICINES PARTNERSHIP PROGRAM IN HEART FAILURE AMP HF, LAUNCHED ON SEPTEMBER 29, 2022, SEEKS TO ADDRESS A CRITICAL UNMET NEED IN CARDIOVASCULAR HEALTH BY BETTER UNDERSTANDING THE PHENOTYPIC DIVERSITY OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) THAT WILL ALLOW FOR THE IDENTIFICATION OF NOVEL PROTEINS OR GENES WITH THE POTENTIAL TO SERVE AS THERAPEUTIC TARGETS.BRINGING TOGETHER RESOURCES FROM THE NIH'S NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI), U.S. FOOD AND DRUG ADMINISTRATION (FDA), AND SEVEN INDUSTRY AND NON-PROFIT PARTNERS, THE AMP HF LAUNCHED WITH COMBINED COMMITMENTS TOTALING $37 MILLION. THE AMP HF INAUGURATION PRECEDED THE HEART FAILURE SOCIETY OF AMERICA'S ANNUAL MEETING AT NATIONAL HARBOR, MARYLAND, WITH REPRESENTATION FROM 17 STAKEHOLDERS FROM INDUSTRY, ACADEMIA, GOVERNMENT, AND NON-PROFIT ORGANIZATIONS.AT THE INAUGURATION, THE NHLBI'S HEARTSHARE PROGRAM HOSTED A WORKSHOP HIGHLIGHTING THE PROGRESS OF SIX CLINICAL CENTERS IN ITS PROGRAM. THE AMP HF BUILDS ON THE INFRASTRUCTURE CREATED BY HEARTSHARE WHOSE GOALS CLOSELY ALIGN WITH THE AMP HF PROJECT: DECONSTRUCTION OF HFPEF SYNDROME LEADING TO THE DISCOVERY OF POTENTIAL THERAPEUTIC TARGETS. SINCE THE AMP HF LAUNCH, THE HEARTSHARE WEBSITE HAS BEEN REBRANDED BRINGING TOGETHER ALL RESOURCES AND KNOWLEDGE UNDER A SINGLE, UNIFIED PORTAL. TO LEARN MORE ABOUT THE AMP HF STUDY DESIGN, PLEASE VISIT THIS ARTICLE BY NATURE REVIEWS DRUG DISCOVERY.REVOLUTIONIZING LIVER DISEASE DIAGNOSIS AND TREATMENT WITH THE NIMBLE INITIATIVENONALCOHOLIC STEATOHEPATITIS, OR NASH, IS A SERIOUS LIVER CONDITION ASSOCIATED WITH OBESITY AND TYPE 2 DIABETES. IT IMPACTS BETWEEN 9 AND 15 MILLION PEOPLE IN THE UNITED STATES. THE CONDITION, WHICH IS A PROGRESSED VERSION OF NONALCOHOLIC FATTY LIVER DISEASE, IS CAUSED BY A BUILDUP OF FAT IN THE LIVER, LEADING TO INFLAMMATION AND SCARRING. INDIVIDUALS WITH NASH OFTEN SHOW VERY FEW EARLY SYMPTOMS. AS A RESULT, THIS ELUSIVE DISEASE FREQUENTLY REMAINS UNDIAGNOSED. MANY PATIENTS ONLY DISCOVER THEY HAVE THE CONDITION AFTER IT HAS PROGRESSED TO CIRRHOSIS, A LATE-STAGE, IRREVERSIBLE FORM OF LIVER SCARRING, OR DEADLY LIVER CANCER.CURRENTLY, AN INVASIVE AND PAINFUL LIVER BIOPSY IS THE ONLY METHOD AVAILABLE TO DIAGNOSE NASH. UNFORTUNATELY, PATIENTS TEND TO BALK AT UNDERGOING REPEATED BIOPSIES OR ENROLLING IN DRUG DEVELOPMENT TRIALS THAT EMPLOY BIOPSIES. WITH THESE CONCERNS IN MIND, FNIH'S NONINVASIVE BIOMARKERS OF METABOLIC LIVER DISEASE (NIMBLE) INITIATIVE IS WORKING TO STANDARDIZE AND COMPARE THE BEST TOOLS FOR DIAGNOSING NASH, INCLUDING NONINVASIVE AND MORE ACCURATE BLOOD-BASED AND IMAGING BIOMARKERS. THE COMPLETED FIRST STAGE OF THE NIMBLE PROJECT HAS SUCCESSFULLY MADE ADVANCEMENTS TOWARDS NONINVASIVE LIVER TESTING. THE FDA HAS ACCEPTED LETTERS OF INTENT (LOIS) FOR 10 NONINVASIVE BIOMARKERS BEING TESTED IN NIMBLE BOTH BLOOD-BASED AND IMAGING-BASED TO SERVE AS ENRICHMENT TOOLS FOR DIAGNOSING "AT RISK" NASH.NIMBLE STAGE 1 FINDINGS DEMONSTRATE THAT NONINVASIVE BIOMARKERS CAN DIAGNOSE "AT RISK" POPULATIONS THAT ARE LIKELY TO PROGRESS TO CIRRHOSIS. THIS WILL REDUCE THE NUMBER OF PATIENTS WHO NEED TO BE CONFIRMED THROUGH BIOPSY PROCEDURES, WHICH THEN REDUCES THE RISK OF MORBIDITY RESULTING FROM BIOPSIES, ENHANCES PATIENT SAFETY, AND BOOSTS THE EFFICIENCY OF CLINICAL TRIALS.THIS IDENTIFICATION OF PATIENTS WHO ARE LIKELY IN THE "AT RISK" CATEGORY ALSO INCREASES THE POTENTIAL FOR THEM TO BE RECRUITED TO CLINICAL TRIALS FOR DEVELOPING DISEASE-ALTERING THERAPIES. THIS REDUCES THE USE OF CLINICAL TRIAL RESOURCES SIGNIFICANTLY, RESULTING IN SUBSTANTIAL COST SAVINGS FOR CLINICAL TRIAL SPONSORS. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $1,173,980 | ExpenseAmt |
| Grant | $543,536 | GrantAmt |
| Desc | SEE SCHEDULE O, PROGRAM TWO, AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMSPROGRAM TWO - AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMS - POWERING SCIENCE: 2022 FNIH AWARDS THE LURIE PRIZE IN BIOMEDICAL SCIENCESIN 2022, THE LURIE PRIZE IN BIOMEDICAL SCIENCES RECOGNIZED THE OUTSTANDING ACHIEVEMENTS OF TWO RESEARCHERS STUDYING THE AGING PROCESS, EACH OF WHOSE WORK HAS PARALLELED AND COMPLEMENTED THE OTHER'S OVER THE PAST 20 YEARS. BOTH WINNERS OF THE 10TH ANNUAL LURIE PRIZE IN BIOMEDICAL SCIENCES HAVE ACHIEVED INCREDIBLE MILESTONES IN BIOMEDICAL SCIENCE, AND THE FNIH IS PROUD TO HONOR THEIR EFFORTS.THE AWARD INCLUDED A $100,000 HONORARIUM, SPLIT BETWEEN THE TWO WINNERS AND MADE POSSIBLE BY A DONATION TO THE FNIH BY PHILANTHROPIST ANN LURIE, PRESIDENT OF THE ANN AND ROBERT H. LURIE FOUNDATION, PRESIDENT OF LURIE HOLDINGS, INC., AND HONORARY FNIH BOARD MEMBER. A DISTINGUISHED JURY OF BIOMEDICAL RESEARCHERS, CHAIRED BY FNIH BOARD MEMBER SOLOMON H. SNYDER, MD, SELECTED THE 2022 WINNERS.2022 AWARD RECIPIENT: ANNE BRUNET, PHD, IS THE MICHELE AND TIMOTHY BARAKETT PROFESSOR OF GENETICS AT STANFORD UNIVERSITY. DR. BRUNET EMPLOYS A UNIQUE MULTI-ORGANISMAL APPROACH TO INVESTIGATE THE ABILITY OF ENZYMES TO REGULATE GENES IMPLICATED IN AGING AND HAS IDENTIFIED GENES AND PATHWAYS CRITICAL FOR MAINTAINING NEURAL STEM CELLS THAT MAY HELP PRESERVE BRAIN FUNCTION DURING AGING. 2022 AWARD RECIPIENT: ANDREW DILLIN, PHD, IS A HOWARD HUGHES MEDICAL INSTITUTE INVESTIGATOR AND THE THOMAS AND STACEY SIEBEL DISTINGUISHED CHAIR IN STEM CELL RESEARCH AT THE DEPARTMENT OF MOLECULAR AND CELL BIOLOGY AT THE UNIVERSITY OF CALIFORNIA, BERKELEY. DR. DILLIN EXPLORES THE ABILITY OF ORGANISMS TO SUSTAIN PROPER PROTEIN PRODUCTION PROCESSES ESSENTIAL TO MAINTAINING CELLULAR STRUCTURE AND FUNCTION IN AGINGTRAILBLAZER PRIZE FOR CLINICIAN-SCIENTISTSTHE FNIH TRAILBLAZER PRIZE FOR CLINICIAN-SCIENTISTS RECOGNIZES THE OUTSTANDING CONTRIBUTIONS OF EARLY CAREER CLINICIAN-SCIENTISTS WHOSE WORK HAS THE POTENTIAL TO, OR HAS LED TO, INNOVATIONS IN PATIENT CARE. IN SEARCHING FOR POTENTIAL WINNERS, WE SEEK TO HIGHLIGHT TRUE SCIENTIFIC INNOVATORS AND THIS YEAR WAS NO EXCEPTION. CONGRATULATIONS WENT TO TWO 2022 TRAILBLAZER PRIZE WINNERS.THIS $10,000 HONORARIUM AND PRIZE, SPLIT BETWEEN THE TWO WINNERS, CELEBRATES THE TRANSFORMATIONAL WORK OF INDIVIDUALS WHOSE RESEARCH TRANSLATES BASIC SCIENTIFIC OBSERVATIONS INTO NEW PARADIGM-SHIFTING APPROACHES FOR DIAGNOSING, PREVENTING, TREATING, OR CURING DISEASE AND DISABILITY. THE TRAILBLAZER PRIZE IS MADE POSSIBLE BY A GENEROUS DONATION FROM JOHN I. GALLIN, MD, AND ELAINE GALLIN, PHD.2022 AWARD RECIPIENT: ELIEZER VAN ALLEN, MD IS ASSOCIATE PROFESSOR OF MEDICINE AT HARVARD MEDICAL SCHOOL, CHIEF OF THE DIVISION OF POPULATION SCIENCES AT THE DANA-FARBER CANCER INSTITUTE, AND ASSOCIATE MEMBER OF THE BROAD INSTITUTE. DR. VAN ALLEN HAS MADE SIGNIFICANT CONTRIBUTIONS TO THE ADVANCEMENT OF THE SCIENCE OF PERSONALIZED CANCER CARE. USING INNOVATIVE COMPUTATIONAL APPROACHES, DR. VAN ALLEN'S RESEARCH IS HELPING DETERMINE THE IMPACT OF BOTH INHERITED AND ENVIRONMENTAL FACTORS ON CANCER AND THE INFLUENCE OF GENES ON AN INDIVIDUAL'S RESPONSE TO CANCER TREATMENT.2022 AWARD RECIPIENT: NIKHIL WAGLE, MD, IS ASSOCIATE PROFESSOR OF MEDICINE AT HARVARD MEDICAL SCHOOL, INSTITUTE MEMBER OF THE BROAD INSTITUTE, AND AN ONCOLOGIST SPECIALIZING IN BREAST CANCER AT THE DANA-FARBER CANCER INSTITUTE. DR. WAGLE DEVELOPED NOVEL GENE SEQUENCING APPROACHES TO PROFILING CANCER MUTATIONS THAT AFFECT TREATMENT RESPONSE AND DRUG RESISTANCE. IN ADDITION, DR. WAGLE DIRECTS COUNT ME IN, AN INNOVATIVE PARTNERSHIP BETWEEN PATIENTS AND RESEARCHERS THAT EMPOWERS PATIENTS TO ACTIVELY PARTICIPATE IN CANCER RESEARCH AND SPEED THE DISCOVERY OF NEW TREATMENTS. CHARLES A. SANDERS, MD, PARTNERSHIP AWARDIN HONOR OF FORMER FNIH CHAIRMAN OF THE BOARD, CHARLES A. SANDERS, MD, WE CELEBRATE OUR PARTNERS AND THEIR CONTRIBUTIONS THROUGH THE ANNUAL PARTNERSHIP AWARD. IN KEEPING WITH DR. SANDERS' VISION, THE AWARD RECOGNIZES PERSONS AND/OR ORGANIZATIONS THAT HAVE MADE SIGNIFICANT CONTRIBUTIONS TO OUR WORK IN CREATING, IMPLEMENTING, AND NURTURING PRIVATE-PUBLIC PARTNERSHIPS THAT BUILD BRIDGES TO BREAKTHROUGHS IN IMPROVED THERAPEUTICS, DIAGNOSTICS, AND POTENTIAL CURES. A COMMITTEE COMPRISED OF FNIH BOARD MEMBERS SELECTED TWO PARTNERS FOR 2022, AMGEN AND FRANCIS S. COLLINS, MD, PHD, WHO HAVE SUPPORTED AND ACCELERATED THE WORK OF THE FNIH FOR MANY YEARS.2022 AWARD RECIPIENT AMGEN: AMGEN'S PARTNERSHIP OVER MANY YEARS HAS HAD A STRONG IMPACT ON A DIVERSE SLATE OF FNIH INITIATIVES, FROM CLINICAL TRIALS TO MENTORSHIPS TO EDUCATIONAL PROGRAMS. GENEROUS FINANCIAL AND SCIENTIFIC SUPPORT FROM AMGEN, A MEMBER OF THE FNIH BIOMARKERS CONSORTIUM, HAS ADVANCED FNIH RESEARCH INITIATIVES IN CANCER, IMMUNOTHERAPY, CARDIOMETABOLIC DISEASE, AND PRECISION MEDICINE. 2022 AWARD RECIPIENT FRANCIS COLLINS, MD, PHD: AS NIH DIRECTOR FROM 2009 TO 2021, DR. FRANCIS S. COLLINS ROBUSTLY SUPPORTED THE MISSION OF THE FNIH, ADVANCING A REMARKABLE LIST OF INITIATIVES TO EXPAND SCIENTIFIC KNOWLEDGE AND PAVE THE WAY FOR HUMAN RIGHTS, PRIVACY ISSUES, AND ETHICS. DR. COLLINS PARTNERED WITH THE NIH'S NATIONAL HUMAN GENOME RESEARCH INSTITUTE AND THE GENETIC ASSOCIATION INFORMATION NETWORK (GAIN) TO CREATE A SIGNIFICANT RESOURCE FOR GENETIC RESEARCHERS. HE HELPED ESTABLISH THE NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS), PROVIDING A CRITICAL VENUE FOR PRECOMPETITIVE PUBLIC-PRIVATE COLLABORATION TO SPEED THE TRANSFORMATION OF BASIC RESEARCH INTO PATIENT THERAPEUTICS. THIS LED TO THE LAUNCH OF THE FNIH-MANAGED ACCELERATING MEDICINES PARTNERSHIP (AMP) PROGRAMA POWERFUL COLLABORATION BETWEEN THE NIH, THE U.S. FOOD AND DRUG ADMINISTRATION (FDA), AND PUBLIC AND PRIVATE ORGANIZATIONS. HE ALSO MANAGED TWO OF THE LARGEST CRISES CHALLENGING HUMAN HEALTH VIA FNIH INITIATIVES: THE HELPING TO END ADDICTION LONG-TERM INITIATIVE (HEAL) AND ACTIV (ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES).EVENTS AND EDUCATIONTHE MEETINGS AND EVENTS DEPARTMENT CONCEPTUALIZES, PLANS, EXECUTES AND EVALUATES HIGH-QUALITY, PRODUCTIVE, INNOVATIVE AND ECONOMICAL CONVENINGS THAT ADVANCE THE ORGANIZATION'S MISSION. THESE CONVENINGS INCLUDE, BUT ARE NOT LIMITED TO, RESEARCH PROJECT TEAM MEETINGS AND CONFERENCES, DONOR STEWARDSHIP LECTURES AND SYMPOSIA AND SPECIAL EVENTS. THE DEPARTMENT OVERSEES THE MANAGEMENT OF FNIH HIGHLY RESPECTED AWARDS AND PRIZES. SOME OF THE FNIH'S MARQUEE EVENTS IN 2022 INCLUDED: THE FNIH AWARDS CEREMONY, THE CANCER STEERING COMMITTEE'S ANNUAL SYMPOSIUM, AND THE GENECONVENE VIRTUAL INSTITUTE WEBINARS SERIES.IN PARTNERSHIP WITH NIH AND OUR PHILANTHROPIC SUPPORTERS, WE FUND AND ADMINISTER TRAINING PROGRAMS THAT PROVIDE OPPORTUNITIES TO STUDENTS OF SCIENCE, FROM HIGH SCHOOLERS TO POST-DOCTORAL SCHOLARS. HERE ARE A FEW EXAMPLES OF THESE PROGRAMS IN ACTION:-ANNUALLY, THE MEDICAL RESEARCH SCHOLARS PROGRAM ENROLLS 50 MEDICAL, DENTAL, AND VETERINARY STUDENTS IN A YEAR-LONG RESEARCH TRAINING AND MENTORSHIP PROGRAM, INCLUDING LECTURES, CLINICAL TEACHING ROUNDS, AND A RESEARCH SYMPOSIUM.-THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE'S HEALTH DISPARITIES IN TRIBAL COMMUNITIES SUMMER INTERNSHIP PROGRAM (HDTC-SIP) PROVIDES STEM EXPOSURE TO STUDENTS FROM UNDERREPRESENTED POPULATIONS.-THE AMGEN SCHOLARS PROGRAM OFFERS SUMMER TRAINING FOR UNDERGRADUATES TO PARTICIPATE IN CUTTING-EDGE RESEARCH.-THE PEW LATIN AMERICAN FELLOWS PROGRAM PROVIDES POST-DOCTORAL TRAINING TO YOUNG STUDENT SCIENTISTS FROM LATIN AMERICA.WE SUPPORT SCIENTISTS AND PROMOTE THEM THROUGH ANNUAL LECTURES AT THE NATIONAL EYE INSTITUTE, THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE, THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, THE NATIONAL CENTER FOR COMPLEMENTARY AND INTEGRATIVE HEALTH, AND ELSEWHERE.MEANWHILE, LEGACY FUNDS FROM INDIVIDUAL BENEFACTORS, SUCH AS THE JAMES T. WENDEL FUND THAT SUPPORTS NEUROLOGICAL RESEARCH IN THE LAB OF NIH'S DR. CARSTEN BONNEMANN, HELP MOVE SCIENTIFIC ACHIEVEMENT FARTHER, FASTER, GIVING HOPE TO FUTURE PATIENTS. THE WILLIAM AND BUFFY CAFRITZ FAMILY FOUNDATION IS ALSO MOVING THE NEEDLE ON NOVEL RESEARCH THROUGH THE PAMELA ANNE CAFRITZ RENAL CELL CARCINOMA AWARD, WHICH SEEKS TO ATTRACT NEW INVESTIGATORS-PARTICULARLY WOMEN-TO KIDNEY CANCER RESEARCH AT THE CENTER FOR CANCER RESEARCH, NATIONAL CANCER INSTITUTE.INDIVIDUAL PROGRAMS, SUCH AS THE SALLIE ROSEN KAPLAN FUND FOR WOMEN SCIENTISTS IN CANCER RESEARCH AND THE DEEDA BLAIR RESEARCH INITIATIVE FOR DISORDERS OF THE BRAIN, PROVIDE FINANCIAL SUPPORT, MENTORING, AND RECOGNITION TO PROMISING YOUNG SCIENTISTS.IN 2022, THE 2021 RECIPIENTS OF THE DEEDA BLAIR RESEARCH INITIATIVE FOR DISORDERS OF THE BRAIN USED THEIR AWARD AND RECOGNITION TO MAKE SIGNIFICANT INROADS IN BOTH THEIR RESEARCH AND THEIR PROFESSIONAL STANDING. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Expenses | $70,388,450 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (1) | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | Yes (1) | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | Yes (1) | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | Yes (1) | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (1) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | Yes (1) | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | 0 | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | 0 | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | Yes (1) | ProfessionalFundraisingInd |
| Fundraising Activities | Yes (1) | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | Yes (1) | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | 0 | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | Yes (1) | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | 0 | RelatedEntityInd |
| Related Organization Ctrl Ent | 0 | RelatedOrganizationCtrlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 46 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 90 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | Yes (1) | QuidProQuoContributionsInd |
| Quid Pro Quo Contri Discl | Yes (1) | QuidProQuoContriDisclInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | 0 | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 25 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 24 | IndependentVotingMemberCnt |
| Family Or Business Rln | 0 | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | 0 | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CO | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | DC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | GA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | HI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | ME | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NV | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NM | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | ND | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | RI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | SC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | UT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WV | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WI | StatesWhereCopyOfReturnIsFldCd |
| Own Website | Yes (X) | OwnWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | DONALD M HILL | PersonNm |
| Phone | 3014356246 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 11400 ROCKVILLE PIKE 600 | AddressLine1Txt |
| City | NORTH BETHESDA | CityNm |
| State Abbreviation | MD | StateAbbreviationCd |
| ZIP | 20852 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (36 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|
| DR STEVEN M PAUL | ||||||||
| CHAIRMAN | 1.50 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| DR SOLOMON H SNYDER | ||||||||
| VICE-CHAIRMAN | 0.50 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| MR STEVEN C MAYER | ||||||||
| TREASURER | 2.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| MRS WILLIAM MCCORMICK BLAIR JR | ||||||||
| SECRETARY | 1.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| DR JULIE L GERBERDING | ||||||||
| CEO (START MAY 2022) | 40.00 | Yes (X) | Yes (X) | $314,575 | $0 | $9,931 | ||
| DR KATHY BLOOMGARDEN | ||||||||
| BOARD MEMBER (UNTIL DEC. 2022) | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR MARIJN DEKKERS | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| MR JAMES H DONOVAN | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR PAUL L HERRLING | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR THOMAS R INSEL | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR JUDY LANSING KOVLER | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR RONALD L KRALL | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR FREDA LEWIS-HALL | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| JULIE BELL LINDSAY | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR EDISON T LIU | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| MR JOEL S MARCUS | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| GILBERT S OMENN | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DAME JILLIAN SACKLER | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| MRS LILY SAFRA | ||||||||
| BOARD MEMBER (UNTIL JULY 2022) | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR CHARLES A SANDERS | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| MR FRED SEIGEL | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR ELLEN V SIGAL | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| MR RUSSELL W STEENBERG | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR PAUL STOFFELS | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR ELIAS ZERHOUNI | ||||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DAVID WHOLLEY | ||||||||
| EXEC. VP, STRATEGY & BUSINESS DEVELOPMENT | 40.00 | Yes (X) | $513,679 | $0 | $38,966 | |||
| DONALD M HILL | ||||||||
| CHIEF FINANCIAL OFFICER | 40.00 | Yes (X) | $277,640 | $0 | $37,972 | |||
| KEVIN A KLOCK | ||||||||
| SR. VP OF OPERATIONS & LEGAL AFFAIRS | 40.00 | Yes (X) | $263,184 | $0 | $34,602 | |||
| MICHAEL SANTOS | ||||||||
| VICE PRESIDENT OF SCIENCE | 40.00 | $348,716 | $0 | $31,698 | Yes (X) | |||
| JULIE WOLF-RODDA | ||||||||
| CHIEF STRATEGIC ALLIANCES & ADVANCEMENT OFFICER | 40.00 | $329,125 | $0 | $38,966 | Yes (X) | |||
| JOSEPH P MENETSKI | ||||||||
| VP OF RESEARCH PARTNERSHIPS | 40.00 | $301,247 | $0 | $36,795 | Yes (X) | |||
| STACEY ADAM | ||||||||
| ASSOCIATE VP, RESEARCH PARTNERSHIPS | 40.00 | $235,748 | $0 | $26,042 | Yes (X) | |||
| STEVEN HOFFMANN | ||||||||
| ASSOCIATE VP, RESEARCH PARTNERSHIPS | 40.00 | $218,627 | $0 | $30,234 | Yes (X) | |||
| COURTNEY SILVERTHORN | ||||||||
| ASSOCIATE VP, RESEARCH PARTNERSHIPS | 40.00 | $211,603 | $0 | $24,500 | Yes (X) | |||
| EVA COYNE | ||||||||
| VICE PRESIDENT & CONTROLLER | 40.00 | $207,270 | $0 | $32,329 | Yes (X) | |||
| DAVID O'BROCHTA | ||||||||
| SCIENTIFIC PROGRAM MANAGER, TECHNICAL LEAD OF GENE | 40.00 | $199,952 | $0 | $31,704 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $3,421,366 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $373,739 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 43 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| SWOG CTI | |||||
| 24 FRANK LLOYD WRIGHT DRIVE PO BOX | ANN ARBOR | MI | 48105 | CLINICAL TRIAL FOR LUNG MAP PROJECT | $7,225,965 |
| DELOITTE CONSULTING LLP | |||||
| 4022 SELLS DRIVE | HERMITAGE | TN | 37076 | COVID-19 PROJECT PROFESSIONAL SERVICES | $2,408,787 |
| DANA-FARBER CANCER INSTITUTE | |||||
| 450 BROOKLINE AVENUE | BOSTON | MA | 02215 | THE PACT, MRD & CTDNA RESEARCH COLLABORA | $1,593,527 |
| THE UNIVERSITY OF TEXASMD ANDERSON | |||||
| PO BOX 4266 | HOUSTON | TX | 77210 | THE PACT PROJECT RESEARCH COLLABORATION | $1,348,679 |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | |||||
| ONE GUSTAVE L LEVY PLACE | NEW YORK | NY | 10029 | THE PACT & THE MUCOSAL HEALING ULCERATIV | $1,097,909 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 30 | CntrctRcvdGreaterThan100KCnt |
| Fundraising | $221,000 | FundraisingAmt |
| Government Grants | $2,000,000 | GovernmentGrantsAmt |
| All Other Contributions | $66,777,263 | AllOtherContributionsAmt |
| Noncash Contributions | $4,121,955 | NoncashContributionsAmt |
| Total Contributions | $68,998,263 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | ADMINISTRATIVE REVENUE | Desc |
| Business | 900099 | BusinessCd |
| Total Revenue Column | $50,000 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $50,000 | RelatedOrExemptFuncIncomeAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $50,000 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $2,204,173 | TotalRevenueColumnAmt |
| Exclusion | $2,204,173 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $137,517,946 | SecuritiesAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $138,262,362 | SecuritiesAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | -$744,416 | SecuritiesAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$744,416 | TotalRevenueColumnAmt |
| Exclusion | -$744,416 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fundraising Gross Income | $430,525 | FundraisingGrossIncomeAmt |
| Contri Rpt Fundraising Event | $221,000 | ContriRptFundraisingEventAmt |
| Fundraising Direct Expenses | $353,346 | FundraisingDirectExpensesAmt |
Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $77,179 | TotalRevenueColumnAmt |
| Exclusion | $77,179 | ExclusionAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $70,585,199 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $50,000 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $1,536,936 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $31,526,028 | TotalAmt |
| Program Services | $31,526,028 | ProgramServicesAmt |
Grants To Domestic Individuals GrantsToDomesticIndividualsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $107,500 | TotalAmt |
| Program Services | $107,500 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $488,047 | TotalAmt |
| Program Services | $488,047 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,577,096 | TotalAmt |
| Program Services | $949,715 | ProgramServicesAmt |
| Management And General | $1,616,338 | ManagementAndGeneralAmt |
| Fundraising | $11,043 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $7,378,822 | TotalAmt |
| Program Services | $5,077,247 | ProgramServicesAmt |
| Management And General | $2,300,194 | ManagementAndGeneralAmt |
| Fundraising | $1,381 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $631,787 | TotalAmt |
| Program Services | $375,329 | ProgramServicesAmt |
| Management And General | $245,919 | ManagementAndGeneralAmt |
| Fundraising | $10,539 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,446,996 | TotalAmt |
| Program Services | $908,822 | ProgramServicesAmt |
| Management And General | $511,386 | ManagementAndGeneralAmt |
| Fundraising | $26,788 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $700,125 | TotalAmt |
| Program Services | $357,994 | ProgramServicesAmt |
| Management And General | $342,131 | ManagementAndGeneralAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $231,734 | TotalAmt |
| Program Services | $174,800 | ProgramServicesAmt |
| Management And General | $55,515 | ManagementAndGeneralAmt |
| Fundraising | $1,419 | FundraisingAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $104,328 | TotalAmt |
| Program Services | $15,750 | ProgramServicesAmt |
| Management And General | $88,578 | ManagementAndGeneralAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $190,215 | TotalAmt |
| Management And General | $190,215 | ManagementAndGeneralAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $22,534 | TotalAmt |
| Program Services | $16,276 | ProgramServicesAmt |
| Management And General | $6,258 | ManagementAndGeneralAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $14,111 | TotalAmt |
| Program Services | $5,007 | ProgramServicesAmt |
| Management And General | $9,104 | ManagementAndGeneralAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $128,139 | TotalAmt |
| Program Services | $27,674 | ProgramServicesAmt |
| Management And General | $42,410 | ManagementAndGeneralAmt |
| Fundraising | $58,055 | FundraisingAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $743,745 | TotalAmt |
| Program Services | $179,469 | ProgramServicesAmt |
| Management And General | $564,276 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,584,497 | TotalAmt |
| Program Services | $1,472,506 | ProgramServicesAmt |
| Management And General | $79,058 | ManagementAndGeneralAmt |
| Fundraising | $32,933 | FundraisingAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $233,480 | TotalAmt |
| Management And General | $233,480 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $241,849 | TotalAmt |
| Program Services | $133,789 | ProgramServicesAmt |
| Management And General | $108,060 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt |
|---|---|---|---|
| PROGRAM CONTRACTS | $23,379,246 | $23,379,246 | |
| CONSULTANTS | $5,078,454 | $4,736,266 | $342,188 |
| BAD DEBT EXPENSE | $200,000 | $200,000 | |
| RECRUITING | $141,708 | $127,196 | $14,512 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $267,669 | TotalAmt |
| Program Services | $129,789 | ProgramServicesAmt |
| Management And General | $137,855 | ManagementAndGeneralAmt |
| Fundraising | $25 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $77,418,110 | TotalAmt |
| Program Services | $70,388,450 | ProgramServicesAmt |
| Management And General | $6,887,477 | ManagementAndGeneralAmt |
| Fundraising | $142,183 | FundraisingAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $47,993,053 | BOYAmt |
| EOY | $73,162,269 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $67,125,693 | BOYAmt |
| EOY | $49,795,550 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $230,354 | BOYAmt |
| EOY | $255,982 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $3,044,663 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $1,473,431 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,725,769 | BOYAmt |
| EOY | $1,571,232 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $101,529,635 | BOYAmt |
| EOY | $84,510,224 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,335,255 | BOYAmt |
| EOY | $7,287,285 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $221,939,759 | BOYAmt |
| EOY | $216,582,542 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $8,537,356 | BOYAmt |
| EOY | $8,918,557 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $338,978 | BOYAmt |
| EOY | $783,334 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,114,103 | BOYAmt |
| EOY | $8,553,216 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $10,990,437 | BOYAmt |
| EOY | $18,255,107 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $28,544,211 | BOYAmt |
| EOY | $27,430,780 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $182,405,111 | BOYAmt |
| EOY | $170,896,655 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $210,949,322 | BOYAmt |
| EOY | $198,327,435 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $221,939,759 | BOYAmt |
| EOY | $216,582,542 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | -$6,832,911 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | -$5,788,976 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Info In Schedule O Part XII | Yes (X) | InfoInScheduleOPartXIIInd |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Separate Basis Fincl Stmt | Yes (X) | SeparateBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (1) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (1) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $60,444,618 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $50,623,645 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $98,343,956 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $105,993,785 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $68,998,263 | CurrentTaxYearAmt |
| Total | $384,404,267 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $60,444,618 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $50,623,645 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $98,343,956 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $105,993,785 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $68,998,263 | CurrentTaxYearAmt |
| Total | $384,404,267 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $133,730,186 | SubstantialContributorsTotAmt |
| Public Support Total170 | $250,674,081 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $2,057,158 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $2,818,334 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $1,722,957 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $1,346,882 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $2,204,173 | CurrentTaxYearAmt |
| Total | $10,149,504 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $394,553,771 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $114,723 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.63530 | PublicSupportCY170Pct |
| Public Support PY170 | 0.59950 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
| Field | Value | IRS element (for citing) |
|---|---|---|
| Volunteers | 0 | VolunteersInd |
| Paid Staff Or Management | Yes (1) | PaidStaffOrManagementInd |
| Media Advertisements | 0 | MediaAdvertisementsInd |
| Mailings Members | 0 | MailingsMembersInd |
| Publications Or Broadcast | 0 | PublicationsOrBroadcastInd |
| Grants Other Organizations | 0 | GrantsOtherOrganizationsInd |
| Direct Contact Legislators | Yes (1) | DirectContactLegislatorsInd |
| Rallies Demonstrations | 0 | RalliesDemonstrationsInd |
| Other Activities | 0 | OtherActivitiesInd |
| Total Lobbying Expenditures | $0 | TotalLobbyingExpendituresAmt |
| Not Described Section501c3 | 0 | NotDescribedSection501c3Ind |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART II-B, LINE 1: | FormAndLineReferenceDesc |
| Explanation | FNIH CONSULTED ITS CONGRESSIONAL COMMITTEES OF JURISDICTION ON PUBLIC HEALTH LEGISLATION. | ExplanationTxt |
Schedule D IRS990ScheduleD
| Field | Value | IRS element (for citing) |
|---|---|---|
| Donor Advised Funds Held | 1 | DonorAdvisedFundsHeldCnt |
| Donor Advised Funds Contri | $3,800 | DonorAdvisedFundsContriAmt |
| Donor Advised Funds Grants | $17,623 | DonorAdvisedFundsGrantsAmt |
| Donor Advised Funds Vl EOY | $203,378 | DonorAdvisedFundsVlEOYAmt |
| Disclosed Org Leg Ctrl | Yes (1) | DisclosedOrgLegCtrlInd |
| Disclosed For Charitable Prps | Yes (1) | DisclosedForCharitablePrpsInd |
| Agent Trustee Etc | 0 | AgentTrusteeEtcInd |
| Incl Escrow Custodial Acct Liab | 0 | InclEscrowCustodialAcctLiabInd |
CY Endwmt Fund CYEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $24,511,134 | BeginningYearBalanceAmt |
| Contributions | -$85,775 | ContributionsAmt |
| Investment Earnings Or Losses | -$788,802 | InvestmentEarningsOrLossesAmt |
| Administrative Expenses | $2,807,342 | AdministrativeExpensesAmt |
| End Year Balance | $20,829,215 | EndYearBalanceAmt |
CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $20,878,035 | BeginningYearBalanceAmt |
| Contributions | $3,154,350 | ContributionsAmt |
| Investment Earnings Or Losses | $544,664 | InvestmentEarningsOrLossesAmt |
| Administrative Expenses | $65,915 | AdministrativeExpensesAmt |
| End Year Balance | $24,511,134 | EndYearBalanceAmt |
CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $14,897,505 | BeginningYearBalanceAmt |
| Contributions | $5,648,998 | ContributionsAmt |
| Investment Earnings Or Losses | $419,982 | InvestmentEarningsOrLossesAmt |
| Administrative Expenses | $88,450 | AdministrativeExpensesAmt |
| End Year Balance | $20,878,035 | EndYearBalanceAmt |
CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $12,514,811 | BeginningYearBalanceAmt |
| Contributions | $1,788,682 | ContributionsAmt |
| Investment Earnings Or Losses | $705,900 | InvestmentEarningsOrLossesAmt |
| Administrative Expenses | $111,888 | AdministrativeExpensesAmt |
| End Year Balance | $14,897,505 | EndYearBalanceAmt |
CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $11,920,726 | BeginningYearBalanceAmt |
| Contributions | $1,032,217 | ContributionsAmt |
| Investment Earnings Or Losses | -$267,231 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $103,397 | OtherExpendituresAmt |
| Administrative Expenses | $67,504 | AdministrativeExpensesAmt |
| End Year Balance | $12,514,811 | EndYearBalanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Board Designated Balance EOY | 0.76819 | BoardDesignatedBalanceEOYPct |
| Prmnnt Endowment Balance EOY | 0.23181 | PrmnntEndowmentBalanceEOYPct |
| Endowments Held Unrelated Org | 0 | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | 0 | EndowmentsHeldRelatedOrgInd |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $1,869,159 | OtherCostOrOtherBasisAmt |
| Depreciation | $590,503 | DepreciationAmt |
| Book Value | $1,278,656 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $1,175,504 | OtherCostOrOtherBasisAmt |
| Depreciation | $882,928 | DepreciationAmt |
| Book Value | $292,576 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $1,571,232 | TotalBookValueLandBuildingsAmt |
Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)
| DescDesc | AmtAmt |
|---|---|
| CHARITABLE GIFT ANNUITY | $114,097 |
| OPERATING LEASE LIABILITY | $8,439,119 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Liability | $8,553,216 | TotalLiabilityAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $65,280,120 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | -$5,788,976 | NetUnrealizedGainsInvstAmt |
| Donated Services And Use Fclts | $320,766 | DonatedServicesAndUseFcltsAmt |
| Revenue Not Reported | -$5,468,210 | RevenueNotReportedAmt |
| Revenue Subtotal | $70,748,330 | RevenueSubtotalAmt |
| Investment Expenses Not Incld | $190,215 | InvestmentExpensesNotIncldAmt |
| Other Revenues Not Included | -$353,346 | OtherRevenuesNotIncludedAmt |
| Revenue Not Reported Fincl Stmt | -$163,131 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $70,585,199 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $77,902,007 | TotExpnsEtcAuditedFinclStmtAmt |
| Donated Services Use Fclts | $320,766 | DonatedServicesUseFcltsAmt |
| Other Expenses Included | $353,346 | OtherExpensesIncludedAmt |
| Expenses Not Reported | $674,112 | ExpensesNotReportedAmt |
| Expenses Subtotal | $77,227,895 | ExpensesSubtotalAmt |
| Investment Expenses Not Incld2 | $190,215 | InvestmentExpensesNotIncld2Amt |
| Expenses Not Rpt Fincl Stmt | $190,215 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $77,418,110 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail (4 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART V, LINE 4: | THE FOUNDATION HAS ONE ENDOWMENT THAT IS FUNDED BY MULTIPLE DONORS TO SEED NEW DISCOVERIES AND/OR BE AVAILABLE TO RESPOND TO EPIDEMICS AND FOUNDATION'S UNANTICIPATED NEEDS. THE FOUNDATION'S OTHER ENDOWMENTS CONSIST OF INDIVIDUAL DONOR-RESTRICTED ENDOWMENT FUNDS ESTABLISHED FOR A VARIETY OF PURPOSE. (E.G. VARIETY OF RESEARCH AND EDUCATIONAL INITIATIVES AT THE FOUNDATION FOR THE NIH, INC). NET ASSETS ASSOCIATED WITH ENDOWMENT FUNDS ARE CLASSIFIED AND REPORTED BASED ON THE EXISTENCE OR ABSENCE OR DONOR-IMPOSED RESTRICTIONS. |
| PART X, LINE 2: | THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE; ACCORDINGLY, THE ACCOMPANYING FINANCIAL STATEMENTS DO NOT REFLECT A PROVISION OR LIABILITY FOR FEDERAL AND STATE INCOME TAXES. THE FOUNDATION HAS DETERMINED THAT IT DOES NOT HAVE ANY MATERIAL UNRECOGNIZED TAX BENEFITS OR OBLIGATIONS AS OF DECEMBER 31, 2022 AND 2021. |
| PART XI, LINE 4B - OTHER ADJUSTMENTS: | FUNDRAISING DIRECT EXPENSE -353,346. |
| PART XII, LINE 2D - OTHER ADJUSTMENTS: | FUNDRAISING DIRECT EXPENSE 353,346. |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (3 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|
| EUROPE (INCLUDING ICELAND & GREENLAND) | 0 | 0 | GRANTMAKING | $426,370 |
| SUB-SAHARAN AFRICA | 0 | 0 | GRANTMAKING | $21,677 |
| NORTH AMERICA | 0 | 0 | GRANTMAKING | $40,000 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 0 | SubtotalEmployeesCnt |
| Continuation Total Office | 0 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 0 | ContinuationTotalEmployeeCnt |
| Total Office | 0 | TotalOfficeCnt |
| Total Employee | 0 | TotalEmployeeCnt |
| Subtotal Spent | $488,047 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $488,047 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (3 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt | Non Cash AssistanceNonCashAssistanceAmt |
|---|---|---|---|---|
| SUB-SAHARAN AFRICA | RESEARCH | $21,677 | WIRE TRANSFER | $0 |
| EUROPE (INCLUDING ICELAND & GREENLAND) | RESEARCH | $426,370 | WIRE TRANSFER | $0 |
| NORTH AMERICA | RESEARCH | $40,000 | WIRE TRANSFER | $0 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 0 | Total501c3OrgCnt |
| Total Other Org | 3 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | 0 | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | 0 | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 2: | PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS SOME DEVELOPING COUNTRY INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. |
| PART III ACCOUNTING METHOD: |
Schedule G IRS990ScheduleG
| Field | Value | IRS element (for citing) |
|---|---|---|
| Mail Solicitations | Yes (X) | MailSolicitationsInd |
| Email Solicitations | Yes (X) | EmailSolicitationsInd |
| In Person Solicitations | Yes (X) | InPersonSolicitationsInd |
| Solicitation Of Govt Grants | Yes (X) | SolicitationOfGovtGrantsInd |
| Special Fundraising Events | Yes (X) | SpecialFundraisingEventsInd |
| Agrmt Prof Fundraising Acty | Yes (1) | AgrmtProfFundraisingActyInd |
Fundraiser Activity Info FundraiserActivityInfoGrp
Organization Business Name OrganizationBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | MICHAEL J WORTH & ASSOCIATES | BusinessNameLine1Txt |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 3622 JENIFER STREET NW | AddressLine1Txt |
| City | WASHINGTON | CityNm |
| State Abbreviation | DC | StateAbbreviationCd |
| ZIP | 20015 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Activity | PLANNED GIVING CONSULTING SERVICES (STRENGTHENING PLANNED GI | ActivityTxt |
| Fundraiser Control Of Funds | 0 | FundraiserControlOfFundsInd |
| Gross Receipts | $0 | GrossReceiptsAmt |
| Retained By Contractor | $15,000 | RetainedByContractorAmt |
| Net To Organization | -$15,000 | NetToOrganizationAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Retained By Contractors | $15,000 | TotalRetainedByContractorsAmt |
| Total Net To Organization | -$15,000 | TotalNetToOrganizationAmt |
| Licensed States | MD | LicensedStatesCd |
| Licensed States | VA | LicensedStatesCd |
| Licensed States | AL | LicensedStatesCd |
| Licensed States | AK | LicensedStatesCd |
| Licensed States | AR | LicensedStatesCd |
| Licensed States | CA | LicensedStatesCd |
| Licensed States | CO | LicensedStatesCd |
| Licensed States | CT | LicensedStatesCd |
| Licensed States | DC | LicensedStatesCd |
| Licensed States | FL | LicensedStatesCd |
| Licensed States | GA | LicensedStatesCd |
| Licensed States | HI | LicensedStatesCd |
| Licensed States | IL | LicensedStatesCd |
| Licensed States | KS | LicensedStatesCd |
| Licensed States | KY | LicensedStatesCd |
| Licensed States | ME | LicensedStatesCd |
| Licensed States | MA | LicensedStatesCd |
| Licensed States | MI | LicensedStatesCd |
| Licensed States | MN | LicensedStatesCd |
| Licensed States | MS | LicensedStatesCd |
| Licensed States | NV | LicensedStatesCd |
| Licensed States | NH | LicensedStatesCd |
| Licensed States | NJ | LicensedStatesCd |
| Licensed States | NM | LicensedStatesCd |
| Licensed States | NY | LicensedStatesCd |
| Licensed States | NC | LicensedStatesCd |
| Licensed States | ND | LicensedStatesCd |
| Licensed States | OH | LicensedStatesCd |
| Licensed States | OK | LicensedStatesCd |
| Licensed States | OR | LicensedStatesCd |
| Licensed States | PA | LicensedStatesCd |
| Licensed States | RI | LicensedStatesCd |
| Licensed States | SC | LicensedStatesCd |
| Licensed States | TN | LicensedStatesCd |
| Licensed States | UT | LicensedStatesCd |
| Licensed States | WA | LicensedStatesCd |
| Licensed States | WV | LicensedStatesCd |
| Licensed States | WI | LicensedStatesCd |
Fundraising Event Information FundraisingEventInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Event1 | 2022 FNIH AWARD CEREMONY | Event1Nm |
| Gross Receipts Event1 | $2,000 | GrossReceiptsEvent1Amt |
| Gross Revenue Event1 | $2,000 | GrossRevenueEvent1Amt |
| Other Direct Expenses Event1 | $2,704 | OtherDirectExpensesEvent1Amt |
| Event2 | 2023 FNIH AWARD CEREMONY | Event2Nm |
| Gross Receipts Event2 | $649,525 | GrossReceiptsEvent2Amt |
| Charitable Contri Event2 | $221,000 | CharitableContriEvent2Amt |
| Gross Revenue Event2 | $428,525 | GrossRevenueEvent2Amt |
| Food And Beverage Event2 | $33,133 | FoodAndBeverageEvent2Amt |
| Other Direct Expenses Event2 | $317,509 | OtherDirectExpensesEvent2Amt |
| Gross Receipts Total | $651,525 | GrossReceiptsTotalAmt |
| Charitable Contributions Tot | $221,000 | CharitableContributionsTotAmt |
| Gross Revenue Total Events | $430,525 | GrossRevenueTotalEventsAmt |
| Food And Beverage Total Events | $33,133 | FoodAndBeverageTotalEventsAmt |
| Oth Direct Expnss Total Events | $320,213 | OthDirectExpnssTotalEventsAmt |
| Direct Expense Summary Events | $353,346 | DirectExpenseSummaryEventsAmt |
| Net Income Summary | $77,179 | NetIncomeSummaryAmt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (30 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Non Cash AssistanceNonCashAssistanceAmt | Purpose Of GrantPurposeOfGrantTxt | Address Line2USAddress/AddressLine2Txt |
|---|---|---|---|---|---|---|---|---|---|
| NIHCC - CLINICAL CENTER | |||||||||
| 9000 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 170(C)(1) GOVERNMENT | $28,754 | $0 | RESEARCH | |
| NIH NIA | |||||||||
| 9001 ROCKVILLE PIKE | BETHESDA | MD | 20893 | 520858116 | 170(C)(1) GOVERNMENT | $2,901,055 | $0 | RESEARCH | |
| NIHNCI | |||||||||
| 9000 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 170(C)(1) GOVERNMENT | $5,827,431 | $0 | RESEARCH | |
| NIHNIAID | |||||||||
| 9000 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 170(C)(1) GOVERNMENT | $5,440,078 | $0 | RESEARCH | |
| NIHNIAMS | |||||||||
| 9000 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 170(C)(1) GOVERNMENT | $3,700,000 | $0 | RESEARCH | |
| NIHNINDS | |||||||||
| 9000 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 170(C)(1) GOVERNMENT | $1,078,415 | $0 | RESEARCH | |
| NIH NHLBI | |||||||||
| 9000 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 170(C)(1) GOVERNMENT | $598,380 | $0 | RESEARCH | |
| NIHOD | |||||||||
| 9000 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 170(C)(1) GOVERNMENT | $99,215 | $0 | RESEARCH | |
| NIH NIMH | |||||||||
| 9000 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 170(C)(1) GOVERNMENT | $3,779,046 | $0 | RESEARCH | |
| RESEARCH TRIANGLE INSTITUTE | |||||||||
| PO BOX 900002 | RALEIGH | NC | 27675 | 560686338 | 501(C)(3) | $1,041,504 | $0 | RESEARCH | |
| UNIVERSITY OF ALABAMA AT BIRMINGHAM | |||||||||
| DEPT OF PEDIATRIC ADMIN LOWDER BLDG | BIRMINGHAM | AL | 35233 | 636001138 | 501(C)(3) | $1,129,930 | $0 | RESEARCH | 608 1600 7TH AVENUE SOUTH |
| THOMAS JEFFERSON UNIVERSITY | |||||||||
| 125 SOUTH 9TH STREET 2ND FLOOR | PHILADELPHIA | PA | 19107 | 231352651 | 501(C)(3) | $498,980 | $0 | RESEARCH | SHERIDAN BUILDING |
| GEORGETOWN UNIVERSITY | |||||||||
| 3700 O STREET NW | WASHINGTON | DC | 20057 | 530196603 | 501(C)(3) | $24,734 | $0 | RESEARCH | |
| UNIVERSITY OF NORTH CAROLINA CHAPEL HILL | |||||||||
| 104 AIRPORT DRIVE SUITE 2200 CAMPUS | CHAPEL HILL | NC | 27599 | 800543561 | 501(C)(3) | $216,595 | $0 | RESEARCH | BOX 1350 |
| THE TRUSTEES OF COLUMBIA UNIVERSITY | |||||||||
| PO BOX 29789 GENERAL POST OFFICE | NEW YORK | NY | 10087 | 135598093 | 501(C)(3) | $287,875 | $0 | RESEARCH | |
| TRUSTEES OF INDIANA UNIVERSITY | |||||||||
| THE POPLARS BUILDING400 E SEVENTH | BLOOMINGTON | IN | 47405 | 356001673 | 501(C)(3) | $228,729 | $0 | RESEARCH | ST |
| UNIVERSITY OF VIRGINIA | |||||||||
| PO BOX 400195 | CHARLOTTESVILLE | VA | 22904 | 546001796 | 501(C)(3) | $176,560 | $0 | RESEARCH | |
| UNIVERSITY OF COLORADO DENVER | |||||||||
| PO BOX 910238 | DENVER | CO | 80291 | 846000555 | 501(C)(3) | $245,158 | $0 | RESEARCH | |
| DUKE UNIVHUMAN VACCINE INSTITUTE | |||||||||
| 2200 WEST MAIN STREET SUITE 820 | DURHAM | NC | 27705 | 560532129 | 501(C)(3) | $179,913 | $0 | RESEARCH | ERWIN SQUARE PLAZA |
| FRED HUTCHINSON CANCER RESEARCH CTR | |||||||||
| 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | 237156071 | 501(C)(3) | $858,905 | $0 | RESEARCH | |
| UNIVERSITY OF PITTSBURGH | |||||||||
| 200 LOTHROP ST BIOMEDICAL SCIENCE | PITTSBURGH | PA | 15213 | 250965591 | 501(C)(3) | $456,993 | $0 | RESEARCH | TOWER W 950 |
| TRUSTEES OF BOSTON UNIVERSITY | |||||||||
| 85 EAST NEWTON STREETM M-921 | BOSTON | MA | 02118 | 042103547 | 501(C)(3) | $593,808 | $0 | RESEARCH | |
| JOHNS HOPKINS UNIVERSITY | |||||||||
| 615 N WOLFE ST W1100 | BALTIMORE | MD | 21205 | 150595110 | 501(C)(3) | $10,000 | $0 | RESEARCH | |
| BRIGHAM & WOMEN'S HOSPITAL | |||||||||
| 1620 TREMONT STREET 3RD FLOOR RM BC | BOSTON | MA | 02120 | 042312909 | 501(C)(3) | $50,000 | $0 | RESEARCH | 3002 |
| FRIENDS OF CANCER RESEARCH | |||||||||
| 1800 M STREET NW SUITE 1050 SOUTH | WASHINGTON | DC | 20036 | 521983273 | 501(C)(3) | $138,296 | $0 | RESEARCH | |
| UNIVERSITY OF SOUTHERN CALIFORNIA | |||||||||
| SOTO STREET BUILDING 2001 SOTO | LOS ANGELES | CA | 90089 | 911642394 | 501(C)(3) | $1,258,000 | $0 | RESEARCH | STREET |
| WESTERN MICHIGAN UNIVERSITY | |||||||||
| 1903 W MICHIGAN AVENUE | KALAMAZOO | MI | 49008 | 386007327 | 501(C)(3) | $17,003 | $0 | RESEARCH | |
| TRANSLATIONAL GENOMICS RESEARCH INSTITUTE | |||||||||
| 446 N FIFTH STREET SUITE 600 | PHOENIX | AZ | 85005 | 331092191 | 501(C)(3) | $86,763 | $0 | RESEARCH | |
| LEIDOS BIOMEDICAL RESEARCH INC | |||||||||
| 1050 BOYLES STREET | FREDERICK | MD | 21702 | 330653185 | CORPORATE ENTITY NOT | $509,908 | $0 | RESEARCH | |
| GORDON RESEARCH CONFERENCES | |||||||||
| 5586 POST ROAD G02 | EAST GREENWICH | RI | 02818 | 260150662 | 501(C)(3) | $64,000 | $0 | RESEARCH | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 29 | Total501c3OrgCnt |
| Total Other Org | 1 | TotalOtherOrgCnt |
Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Type | AWARDS | GrantTypeTxt |
| Recipient | 4 | RecipientCnt |
| Cash Grant | $107,500 | CashGrantAmt |
| Valuation Method Used | FMV | ValuationMethodUsedDesc |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS FOR-PROFIT INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. FELLOWS SELECTED FOR FOUNDATION FELLOWSHIPS ARE SELECTED THROUGH NATIONWIDE AND INTERNATIONAL COMPETITIONS. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Housing Allowance Or Residence | Yes (X) | HousingAllowanceOrResidenceInd |
| Written Policy Ref T And E Expnss | Yes (1) | WrittenPolicyRefTAndEExpnssInd |
| Substantiation Required | Yes (1) | SubstantiationRequiredInd |
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Written Employment Contract | Yes (X) | WrittenEmploymentContractInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | 0 | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (12 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DAVID WHOLLEY | ||||||||||||||
| EXEC. VP, STRATEGY & BUSINESS DEVELO | $393,629 | $0 | $109,250 | $0 | $10,800 | $0 | $24,400 | $0 | $14,566 | $0 | $552,645 | $0 | $0 | $0 |
| MICHAEL SANTOS | ||||||||||||||
| VICE PRESIDENT OF SCIENCE | $348,716 | $0 | $0 | $0 | $0 | $0 | $24,400 | $0 | $7,298 | $0 | $380,414 | $0 | $0 | $0 |
| JULIE WOLF-RODDA | ||||||||||||||
| CHIEF STRATEGIC ALLIANCES & ADVANCEM | $274,225 | $0 | $54,900 | $0 | $0 | $0 | $24,400 | $0 | $14,566 | $0 | $368,091 | $0 | $0 | $0 |
| JOSEPH P MENETSKI | ||||||||||||||
| VP OF RESEARCH PARTNERSHIPS | $265,247 | $0 | $36,000 | $0 | $0 | $0 | $24,229 | $0 | $12,566 | $0 | $338,042 | $0 | $0 | $0 |
| DR JULIE L GERBERDING | ||||||||||||||
| CEO (START MAY 2022) | $311,515 | $0 | $0 | $0 | $3,060 | $0 | $0 | $0 | $9,931 | $0 | $324,506 | $0 | $0 | $0 |
| DONALD M HILL | ||||||||||||||
| CHIEF FINANCIAL OFFICER | $267,640 | $0 | $10,000 | $0 | $0 | $0 | $22,556 | $0 | $15,416 | $0 | $315,612 | $0 | $0 | $0 |
| KEVIN A KLOCK | ||||||||||||||
| SR. VP OF OPERATIONS & LEGAL AFFAIRS | $255,184 | $0 | $8,000 | $0 | $0 | $0 | $21,336 | $0 | $13,266 | $0 | $297,786 | $0 | $0 | $0 |
| STACEY ADAM | ||||||||||||||
| ASSOCIATE VP, RESEARCH PARTNERSHIPS | $225,748 | $0 | $10,000 | $0 | $0 | $0 | $18,844 | $0 | $7,198 | $0 | $261,790 | $0 | $0 | $0 |
| STEVEN HOFFMANN | ||||||||||||||
| ASSOCIATE VP, RESEARCH PARTNERSHIPS | $213,627 | $0 | $5,000 | $0 | $0 | $0 | $17,668 | $0 | $12,566 | $0 | $248,861 | $0 | $0 | $0 |
| EVA COYNE | ||||||||||||||
| VICE PRESIDENT & CONTROLLER | $200,270 | $0 | $7,000 | $0 | $0 | $0 | $17,013 | $0 | $15,316 | $0 | $239,599 | $0 | $0 | $0 |
| COURTNEY SILVERTHORN | ||||||||||||||
| ASSOCIATE VP, RESEARCH PARTNERSHIPS | $211,603 | $0 | $0 | $0 | $0 | $0 | $16,942 | $0 | $7,558 | $0 | $236,103 | $0 | $0 | $0 |
| DAVID O'BROCHTA | ||||||||||||||
| SCIENTIFIC PROGRAM MANAGER, TECHNICA | $199,952 | $0 | $0 | $0 | $0 | $0 | $16,288 | $0 | $15,416 | $0 | $231,656 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 1A | FormAndLineReferenceDesc |
| Explanation | WE PROVIDED A STIPEND FOR HOUSING TO OUR CEO. THE TERMS FOR THIS STIPEND ARE SET FORTH IN THE CEO'S EMPLOYMENT AGREEMENT. | ExplanationTxt |
Schedule M IRS990ScheduleM
Drugs And Medical Supplies DrugsAndMedicalSuppliesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 7 | ContributionCnt |
| Noncash Contributions Rpt F990 | $4,121,956 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | FMV | MethodOfDeterminingRevenuesTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Any Property That Must Be Held | 0 | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | 0 | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | 0 | ThirdPartiesUsedInd |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (8 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART III, LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS CONTINUED: | NIMBLE'S INNOVATIVE APPROACH HAS ALREADY SHOWN INCREDIBLE POTENTIAL FOR REVOLUTIONIZING MEDICAL RESEARCH AND PATIENT CARE. AS A RESULT OF THE INITIATIVE'S ACHIEVEMENTS, NUMEROUS ABSTRACTS WERE PRESENTED AT THE ANNUAL AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES (AASLD) CONFERENCE AND THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER (EASL) CONFERENCE. MOREOVER, CORRESPONDENCE WAS PUBLISHED IN THE HIGH-IMPACT JOURNAL NATURE MEDICINE HIGHLIGHTING THE PROGRAM'S FINDINGS TO DATE. STRENGTHENING THE PATIENT VOICE WITH DIGITAL MEASURES WORKSHOPS OVER THE PAST FEW YEARS, THE FNIH BIOMARKERS CONSORTIUM HAS LAUNCHED A SERIES OF DIGITAL MEASURES WORKSHOPS DESIGNED TO BRING REGULATORS, PAYERS, AND PATIENTS TOGETHER TO STREAMLINE DIGITAL MEASURE DEVELOPMENT AND IMPLEMENTATION PROCESSES. THE FIRST WORKSHOP, WHICH WAS CONDUCTED IN FEBRUARY 2020, WAS INSTRUMENTAL IN HELPING THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) BRING FORWARD THE INNOVATIVE SCIENCE AND TECHNOLOGY APPROACHES FOR NEW DRUGS (ISTAND) PROGRAM. THE WORKSHOP ALSO HELPED THE FDA REDEFINE ITS NOMENCLATURE AROUND DIGITAL HEALTH AND BIOMARKERS AND FOCUS ON DIGITAL MEASURES. THE FNIH BIOMARKERS CONSORTIUM HOSTED ITS SECOND DIGITAL MEASURES WORKSHOP SEPTEMBER 2022 IN ZURICH, SWITZERLAND, WITH A GOAL OF EMPHASIZING PATIENT-CENTRICITY IN SHAPING AND IMPROVING HOW DIGITAL MEASURES ARE IDENTIFIED, DESIGNED, AND IMPLEMENTED. THIS WORKSHOP ESTABLISHED A GLOBAL FOOTPRINT FOR FNIH AND ITS PARTNERS, ENGAGING THE EUROPEAN MEDICINES AGENCY (EMA) AND OTHER INTERNATIONAL PARTNERS IN A WAY THAT HADN'T BEEN PREVIOUSLY POSSIBLE. A THIRD FUTURE WORKSHOP WILL PROVIDE THE CRITICAL LINK BETWEEN NIH, REGULATORS, AND INDUSTRY TO ENSURE THAT ALL PLAYERS HAVE A SEAT AT THE TABLE, THAT PATIENTS ARE INCLUDED, AND THAT THE FIELD CAN COLLECTIVELY IDENTIFY PROCESSES AND CHECKS SO THAT DIGITAL HEALTH LEADS TO USEFUL TOOLS, NOT JUST MORE GADGETS. RESEARCH PROGRAMS FOR ADVANCING GLOBAL HEALTH PREVENTING SEPSIS IN LABORING MOTHERS WORLDWIDE MATERNAL AND NEONATAL SEPSIS IS ONE OF THE TOP THREE CAUSES OF MATERNAL AND NEWBORN DEATHS GLOBALLY. TO ADDRESS THIS PRESSING ISSUE AND URGENT GLOBAL NEED, THE AZITHROMYCIN PREVENTION IN LABOR USE STUDY (A-PLUS) WAS CONDUCTED BY THE EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT (NICHD)'S GLOBAL NETWORK FOR WOMEN'S AND CHILDREN'S HEALTH RESEARCH AND WAS CO-FUNDED BY NICHD AND THE FNIH, WITH SUPPORT TO THE FNIH PROVIDED BY A GRANT FROM THE BILL & MELINDA GATES FOUNDATION. THE STUDY ASSESSED LOW-COST, SUSTAINABLE INTERVENTIONS TO IMPROVE MATERNAL AND CHILD HEALTH IN LOW- AND MIDDLE-INCOME COUNTRIES. AFTER A RIGOROUS PROCESS OF TRAINING AND PILOT-TESTING, INVESTIGATORS EXAMINED THE SAFETY AND EFFECTIVENESS OF A SINGLE ORAL DOSE OF AZITHROMYCIN ADMINISTERED DURING LABOR (COMPARED TO PLACEBO) IN REDUCING THE RISK OF NEONATAL AND MATERNAL SEPSIS OR DEATH IN LABORING WOMEN. THE RESULTS WERE VERY PROMISING, SUGGESTING THAT AZITHROMYCIN CAN REDUCE THE OCCURRENCE OF MATERNAL SEPSIS AND DEATH BY APPROXIMATELY ONE-THIRD. FOLLOWING THE STUDY, INVESTIGATORS RAPIDLY ANALYZED THE QUALITY OF THE DATA AND RESULTS TO ENABLE OPEN ACCESS TO THE FINDINGS IN A TIMELY MANNER. AN ABSTRACT WAS SUBMITTED TO THE WORLD'S PREMIER PREGNANCY CONFERENCE, THE SOCIETY FOR MATERNAL-FETAL MEDICINE'S ANNUAL PREGNANCY MEETING (SMFM). THE ABSTRACT WAS ACCEPTED AND BECAME THE #1 LATE-BREAKING PRESENTATION AT THE CONFERENCE IN FEBRUARY 2023. THE STUDY INVESTIGATORS ALSO SUBMITTED A MANUSCRIPT TO THE NEW ENGLAND JOURNAL OF MEDICINE (NEJM), WHICH WAS ACCEPTED AND PUBLISHED AS THE CONFERENCE PRESENTATION WAS BEING DELIVERED. AS A NEXT STEP, THE A-PLUS INVESTIGATORS WILL FOLLOW UP WITH A SUBSET OF THE MOTHERS AND INFANTS TO EXAMINE POTENTIAL ANTIMICROBIAL RESISTANCE AT MULTIPLE POINTS IN TIME, UP TO A YEAR AFTER INITIAL DELIVERY, AS A FURTHER SAFETY MEASURE. THE STUDY FINDINGS COULD RESULT IN A CHANGE TO THE CURRENT STANDARD OF CARE BY ADDING THIS SIMPLE PREVENTIVE INTERVENTION AN ADJUSTMENT THAT COULD SAVE MILLIONS OF LIVES. REDUCING ANEMIA IN POSTPARTUM WOMEN IRON DEFICIENCY ANEMIA REMAINS A MAJOR CONTRIBUTOR TO MATERNAL ILLNESS AND MORTALITY WORLDWIDE, AND DESPITE NUMEROUS EFFORTS, RATES OF ANEMIA HAVE NOT DECREASED IN LOW- AND MIDDLE-INCOME COUNTRIES. THANKFULLY, INTRAVENOUS IRON TREATMENTS HAVE BEEN DEMONSTRATED TO BE A SAFE, EFFECTIVE INTERVENTION TO REDUCE ANEMIA DURING PREGNANCY. HOWEVER, INTRAVENOUS IRON TREATMENTS HAVE NOT BEEN COMPREHENSIVELY ASSESSED DURING THE POSTPARTUM PERIOD UNTIL NOW. FIRST LAUNCHED IN NOVEMBER 2022, THE PREVENTION OF IRON DEFICIENCY ANEMIA POST-DELIVERY (PRIORITY) TRIAL AIMS TO DETERMINE IF A SINGLE-DOSE INTRAVENOUS IRON INFUSION IS MORE EFFECTIVE THAN THE CURRENT STANDARD OF CARE ORAL IRON SUPPLEMENTATION AMONG POSTPARTUM WOMEN WITH MODERATE ANEMIA IN LOW- AND MIDDLE-INCOME COUNTRIES. IN ADDITION TO COMPARING OUTCOMES FOR TREATING ANEMIA, RESEARCHERS ARE ASSESSING TRIAL PARTICIPANTS FOR IMPORTANT SECONDARY OUTCOMES RELATED TO ANEMIA, PARTICULARLY POSTPARTUM DEPRESSION, WHICH CAN AFFECT MATERNAL QUALITY OF LIFE, FATIGUE, BREASTFEEDING INITIATION AND RETENTION RATES, AND INFANT-MOTHER BONDING. THE STUDY RESULTS ARE EXPECTED TO BE USEFUL FOR INFORMING NATIONAL HEALTH POLICIES AND PRACTICES, IMPROVING THE CARE OF WOMEN. ADVISING ON AN HISTORIC GLOBAL PANDEMIC TREATY AT AN HISTORIC GATHERING IN 2021, 173 MEMBER GOVERNMENTS OF THE WORLD HEALTH ORGANIZATION (WHO) RESOLVED TO NEGOTIATE AN INTERNATIONAL AGREEMENT ON PANDEMIC PREPAREDNESS AND RESPONSE. THE FNIH, IN PARTNERSHIP WITH WHO'S COLLABORATING CENTER AT GEORGETOWN UNIVERSITY'S O'NEILL INSTITUTE FOR NATIONAL AND GLOBAL HEALTH LAW, CONVENED DOZENS OF LEADING EXPERTS FROM AROUND THE WORLD TO PROVIDE TECHNICAL ADVICE AND LEARNINGS TO POLICYMAKERS, MEMBER STATES, AND THE PUBLIC. ON THE HEELS OF THE CONSORTIUM'S REPORT ON LEGAL TOOLS FOR PANDEMIC PREPAREDNESS, THE FNIH AND O'NEILL INSTITUTE ALSO BROUGHT TOGETHER THOUGHT LEADERS TO CONSIDER THE NATIONAL SOVEREIGNTY IMPLICATIONS OF A PANDEMIC INSTRUMENT, AND TO ANALYZE THE RANGE OF AGREEMENTS PREVIOUSLY DEPLOYED TO COORDINATE INTERNATIONAL ACTIVITY AND HOW THEY MIGHT INFORM A TREATY ADDRESSING CATASTROPHIC EPIDEMIC EVENTS. IN ADDITION, THE FNIH'S KEVIN A. KLOCK, WHO CO-CHAIRS THE INITIATIVE WITH THE O'NEILL INSTITUTE'S LAWRENCE O. GOSTIN, PUBLISHED A SERIES OF SUPPORTING PAPERS IN PROMINENT JOURNALS AND OUTLETS, INCLUDING THE LANCET, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, STAT, AND THINK GLOBAL HEALTH. A THIRD CONVENING, CO-LED WITH THE JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS (UNAIDS), COMMENCED IN THE SECOND HALF OF 2022 AND LED TO A 2023 REPORT CALLED ADVANCING A WORLD TOGETHER EQUITABLY, WHICH EXPLORES EXISTING MECHANISMS THAT ASSERT EQUITY AS A PRIORITY AND ANALYZED HOW THEY COULD BE INCORPORATED INTO A TREATY. |
| FORM 990, PART VI, SECTION A, LINE 1A | THE BOARD HAS AN EXECUTIVE COMMITTEE, WHICH CAN MAKE DECISIONS ON BEHALF OF THE BOARD (WITH SOME EXCEPTIONS) IN BETWEEN BOARD MEETINGS. |
| FORM 990, PART VI, SECTION B, LINE 11B | PRIOR TO THE SUBMISSION OF THE FOUNDATION FOR NIH'S FORM 990 TO THE INTERNAL REVENUE SERVICE, EACH VOTING MEMBER OF THE BOARD OF DIRECTORS SHALL BE PROVIDED WITH A COPY OF THE DRAFT FORM 990 AS APPROVED BY THE CHIEF FINANCIAL OFFICER. |
| FORM 990, PART VI, SECTION B, LINE 12C | DIRECTORS, OFFICERS AND EMPLOYEES ARE REQUIRED TO ANNUALLY SIGN A STATEMENT WHICH AFFIRMS THAT THEY HAVE: O RECEIVED A COPY OF THE CONFLICT OF INTEREST POLICY O READ, UNDERSTOOD AND AGREED TO COMPLY WITH THE POLICY O RECEIVED AND REVIEWED A LISTING OF CORPORATE AND FOUNDATION DONORS, CONTRACTORS, VENDORS, GRANTEES, PRINCIPAL INVESTIGATORS AND FINANCIAL INSTITUTIONS WITH WHOM THE FNIH HAS A CURRENT RELATIONSHIP O NO ACTUAL OR APPARENT CONFLICTS OF INTEREST OTHER THAN THOSE DISCLOSED IN THE STATEMENT. THEY MUST ALSO MAKE CERTAIN NOTIFICATIONS IN PARTICULAR CIRCUMSTANCES. THE CONFLICT OF INTEREST POLICY ALSO HAS MECHANISMS FOR HANDLING SUCH CONFLICTS. |
| FORM 990, PART VI, SECTION B, LINE 15 | THE COMPENSATION COMMITTEE OF THE BOARD REVIEWED AND CONCURRED WITH THE CEO'S DECISIONS ESTABLISHING AND ADJUSTING THE SENIOR EXECUTIVE TEAM'S ANNUAL SALARIES AND RELATED COMPENSATION DECISIONS. THE COMPENSATION COMMITTEE ALSO APPROVED THE COMPENSATION LEVEL OF THE CEO AND RELATED COMPENSATION DECISIONS. |
| FORM 990, PART VI, SECTION C, LINE 19 | ALL SUCH DOCUMENTS ARE AVAILABLE UPON REQUEST. IN ADDITION, THE GOVERNING DOCUMENTS AND FINANCIAL STATEMENTS ARE AVAILABLE ON THE FNIH WEBSITE. |
| FORM 990, PART XII, LINE 2C: | PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR. |
| FORM 990, PART X, CASH & INVESTMENTS: | APPROXIMATELY $122 MILLION OF FNIH'S CASH AND INVESTMENTS ARE INVESTED IN HIGH QUALITY SHORT-TERM FIXED INCOME SECURITIES WHICH ARE COMMITTED TO FNIH'S RESTRICTED ASSETS. |